1. Does pulmonary rehabilitation (PR) reduce mortality risk? 2. Does PR in the post-hospitalization period reduce subsequent health care utilization? 3. Can the principles of PR be applied more broadly across the disease spectrum to reduce morbidity, mortality, and health care expenditures in patients with COPD? 4. Does early PR following hospitalization for acute exacerbation reduce mortality and readmission rates ...more »
What are the biomarkers that identify expression and progression of specific subtypes of chronic lung disease?
How can chest CT or other imaging tools be optimally used to characterize expression and progression of chronic lung disease?
What barriers and facilitators modify the effectiveness of smoking cessation programs in patients with COPD?
Integrated healthcare strategies during transitions in COPD care
• What is cost effectiveness of multi-component COPD programs?
• Will early admission to a Pulmonary Rehabilitation program following a hospitalization for COPD reduce the likelihood of readmission within the following year?
• What is the most effective time to implement the transition from hospitalization following a COPD exacerbation admission?
Lead a coordinated effort of government, patient advocacy organizations, professional organizations, payers and others to plan and implement a coordinated plan to improve COPD awareness, education for patients and healthcare professionals, treatment strategies, research and data collection, policies and public health infrastructure and programs.
Incorporate important co-morbidities of COPD into treatment guidelines. This becomes crucially important with cardiovascular disease (CVD) which shares risk factors and pathogenesis
Disease modifying COPD therapy
a. Should we be starting therapy earlier in the course of disease?
b. Is there a survival benefit of oxygen therapy for exercise-induced hypoxemia?
What is the validity of administrative/billing data to evaluate the quality of COPD care as part of quality improvement initiatives? What care practices can be assessed using these data?
What factors serve as barriers / facilitators for patient adherence to pulmonary rehabilitation for COPD care?
Integration of multiple Omics data types (genetics, transcriptomics, metabolomics, proteomics, and epigenetics) to understand susceptibility, progression, and heterogeneity of chronic lung diseases.
Can Measuring CD31+EMPs predict loss of lung function, provide potential bio marker for accelerated lung function loss, and predict increased risk for atherosclerosis leading to increased risk for cardiovascular events?